An adverse lipid profile is associated with disability and progression in disability, in people with MS

Multiple Sclerosis Journal

Volumn 20, Issue 13, 2014, Pages 1737-1744

  Tettey, Prudence ^a   Simpson, Steve ^a   Taylor, Bruce ^a   Blizzard, Leigh ^a   Ponsonby, Anne Louise ^b   Dwyer, Terence ^b   Kostner, Karam ^c   Van Der Mei, Ingrid ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Apolipoprotein; Body mass index; Cholesterol; Disability; Lipid profile; Multiple sclerosis; Progression

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LIPID; APOLIPOPROTEIN; APOLIPOPROTEIN E; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; AUSTRALIA; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HYPERTENSION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBESITY; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; BLOOD; COHORT ANALYSIS; MIDDLE AGED; YOUNG ADULT; LIPOPROTEIN BLOOD LEVEL; POPULATION RESEARCH;

ADULT; AGED; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 84911432514     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514533162     Document Type: Article

References (35)

1. Al-Omaishi J, Bashir R and Gendelman HE. The cellular immunology of multiple sclerosis. J Leukoc Biol 1999; 65: 444-452.
2. Balazs Z, Panzenboeck U, Hammer A, et al. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem 2004; 89: 939-950.
3. Newcombe J, Li H and Cuzner ML. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: Implications for pathogenesis. Neuropathol Appl Neurobiol 1994; 20: 152-162.
4. Koch S, Donarski N, Goetze K, et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001; 42: 1143-1151.
5. Adibhatla RM and Hatcher JF. Role of lipids in brain injury and diseases. Future Lipidol 2007; 2: 403-422.
6. Del Boccio P, Pieragostino D, Di Ioia M, et al. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteom 2011; 74: 2826-2836.
7. Gilgun-Sherki Y, Melamed E and Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J Neurol 2004; 251: 261-268.
8. Khurana SR, Bamer AM, Turner AP, et al. The prevalence of overweight and obesity in veterans with multiple sclerosis. Am J Phys Med Rehabil 2009; 88: 83-91.
9. Pilutti LA, Dlugonski D, Pula JH, et al. Weight status in persons with multiple sclerosis: Implications for mobility outcomes. J Obes 2012; 2012: 868256.
10. Karmon Y, Ramanathan M, Minagar A, et al. Arterial, venous and other vascular risk factors in multiple sclerosis. Neurol Res 2012; 34: 754-760.
11. Munger KL, Chitnis T and Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 2009; 73: 1543-1550.
12. Hedstrom AK, Olsson T and Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18: 1334-1336.
13. Giubilei F, Antonini G, Di Legge S, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 2002; 106: 109-112.
14. Browne RW, Weinstock-Guttman B, Horakova D, et al. Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. J Neurol Neurosurg Psychiatr 2014.
15. Weinstock-Guttman B, Zivadinov R, Horakova D, et al. Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatr 2013; 84: 1186-1191.
16. Kardys A, Weinstock-Guttman B, Dillon M, et al. Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. Eur J Neurol 2013; 20: 1264-1271.
17. Weinstock-Guttman B, Zivadinov R, Mahfooz N, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflamm 2011; 8: 127.
18. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
19. Pittas F, Ponsonby AL, Van der Mei IA, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009; 256: 577-585.
20. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
21. Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: Do we need to revisit the oral triglyceride tolerance test? Clin Chem 2008; 54: 11-13.
22. Fukuyama N, Homma K, Wakana N, et al. Validation of the Friedewald equation for evaluation of plasma LDL-cholesterol. J Clin Biochem Nutrit 2008; 43: 1-5.
23. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776-785.
24. Available at: http://www.heart.org/HEARTORG/Conditions/Cholesterol/AboutCholesterol/What-Your-Cholesterol-Levels-Mean-UCM-305562-Article.jsp. Accessed June 5, 2013.
25. Gostynski M, Gutzwiller F, Kuulasmaa K, et al. Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project. Int J Obes Relat Metab Disord 2004; 28: 1082-1090.
26. Faheem M, Qureshi S, Ali J, et al. Does BMI affect cholesterol, sugar, and blood pressure in general population? J Ayub Med Coll Abbottabad 2010; 22: 74-77.
27. Schroder H, Marrugat J, Elosua R, et al. Relationship between body mass index, serum cholesterol, leisure-time physical activity, and diet in a Mediterranean Southern-Europe population. Br J Nutr 2003; 90: 431-439.
28. Palavra F, Marado D, Mascarenhas-Melo F, et al. New markers of early cardiovascular risk in multiple sclerosis patients: Oxidized-LDL correlates with clinical staging. Dis Markers 2013; 34: 341-348.
29. Pilutti LA, McAuley E and Motl RW. Weight status and disability in multiple sclerosis: An examination of bi-directional associations over a 24-month period. Mult Scler Rel Disord 2012; 1: 139-144.
30. Chataway J, Schuerer N, Alsanousi A, et al. The MS-STAT Trial: High dose simvastatin slows brain atrophy and delays disability in secondary progressive multiple sclerosis: A Phase II placebo-controlled trial. Neurology 2013; 80: PL02.001.
31. Janus ED, Tideman PA, Dunbar JA, et al. Dyslipidaemia in rural Australia: Prevalence, awareness, and adherence to treatment guidelines in the Greater Green Triangle Risk Factor Study. Med J Aust 2010; 192: 127-132.
32. Assmann G, Cullen P and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-315.
33. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 407-419.
34. Maki KC, Rubin MR, Wong LG, et al. Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and women. J Clin Lipidol 2009; 3: 289-296.
35. Sidhu D and Naugler C. Fasting time and lipid levels in a community-based population: A cross-sectional study. Arch Intern Med 2012; 172: 1707-1710.